Posted by Michael Wonder on 13 Feb 2025
Medical imaging agent gozetotide approved for diagnosis of prostate cancer
12 February 2025 - Gozetotide binds to the cancer cells with prostate-specific membrane antigen on their surface, making them visible during the positron emission tomography scan.
The MHRA has today approved gozetotide (Illuccix) to be used in a type of medical imaging procedure called a position emission tomography scan which is used to detect specific types of cancer cells in adults with prostate cancer.
